-
Something wrong with this record ?
Assessing disease progression and treatment response in progressive multiple sclerosis
G. Comi, G. Dalla Costa, B. Stankoff, HP. Hartung, P. Soelberg Sørensen, P. Vermersch, L. Leocani
Language English Country England, Great Britain
Document type Journal Article, Review
NLK
ProQuest Central
from 2009-04-01 to 1 year ago
Health & Medicine (ProQuest)
from 2009-04-01 to 1 year ago
- MeSH
- Biomarkers blood MeSH
- Multiple Sclerosis, Chronic Progressive * therapy diagnostic imaging MeSH
- Humans MeSH
- Magnetic Resonance Imaging methods MeSH
- Disease Progression * MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease progression and treatment response owing to its multifaceted pathophysiology. Traditional clinical measures such as the Expanded Disability Status Scale are limited in capturing the full scope of disease and treatment effects. Advanced imaging techniques, including MRI and PET scans, have emerged as valuable tools for the assessment of neurodegenerative processes, including the respective role of adaptive and innate immunity, detailed insights into brain and spinal cord atrophy, lesion dynamics and grey matter damage. The potential of cerebrospinal fluid and blood biomarkers is increasingly recognized, with neurofilament light chain levels being a notable indicator of neuro-axonal damage. Moreover, patient-reported outcomes are crucial for reflecting the subjective experience of disease progression and treatment efficacy, covering aspects such as fatigue, cognitive function and overall quality of life. The future incorporation of digital technologies and wearable devices in research and clinical practice promises to enhance our understanding of functional impairments and disease progression. This Review offers a comprehensive examination of these diverse evaluation tools, highlighting their combined use in accurately assessing disease progression and treatment efficacy in progressive multiple sclerosis, thereby guiding more effective therapeutic strategies.
Brain and Mind Center University of Sydney Sydney Australia
Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Germany
Department of Neurology Palacky University Olomouc Olomouc Czech Republic
Department of Neurorehabilitation Sciences Casa di Cura Igea Milan Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004010
- 003
- CZ-PrNML
- 005
- 20250206105037.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41582-024-01006-1 $2 doi
- 035 __
- $a (PubMed)39251843
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Comi, Giancarlo $u Department of Neurorehabilitation Sciences, Casa di Cura Igea, Milan, Italy. g.comi@comigiancarlo.com
- 245 10
- $a Assessing disease progression and treatment response in progressive multiple sclerosis / $c G. Comi, G. Dalla Costa, B. Stankoff, HP. Hartung, P. Soelberg Sørensen, P. Vermersch, L. Leocani
- 520 9_
- $a Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease progression and treatment response owing to its multifaceted pathophysiology. Traditional clinical measures such as the Expanded Disability Status Scale are limited in capturing the full scope of disease and treatment effects. Advanced imaging techniques, including MRI and PET scans, have emerged as valuable tools for the assessment of neurodegenerative processes, including the respective role of adaptive and innate immunity, detailed insights into brain and spinal cord atrophy, lesion dynamics and grey matter damage. The potential of cerebrospinal fluid and blood biomarkers is increasingly recognized, with neurofilament light chain levels being a notable indicator of neuro-axonal damage. Moreover, patient-reported outcomes are crucial for reflecting the subjective experience of disease progression and treatment efficacy, covering aspects such as fatigue, cognitive function and overall quality of life. The future incorporation of digital technologies and wearable devices in research and clinical practice promises to enhance our understanding of functional impairments and disease progression. This Review offers a comprehensive examination of these diverse evaluation tools, highlighting their combined use in accurately assessing disease progression and treatment efficacy in progressive multiple sclerosis, thereby guiding more effective therapeutic strategies.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a progrese nemoci $7 D018450
- 650 12
- $a chronicko-progresivní roztroušená skleróza $x terapie $x diagnostické zobrazování $7 D020528
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 650 _2
- $a biologické markery $x krev $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dalla Costa, Gloria $u Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Stankoff, Bruno $u Sorbonne Université, Paris Brain Institute, Institut du Cerveau et de la Moelle Épinière, Centre National de la Recherche Scientifique, Inserm, Paris, France
- 700 1_
- $a Hartung, Hans-Peter $u Brain and Mind Center, University of Sydney, Sydney, Australia $u Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
- 700 1_
- $a Soelberg Sørensen, Per $u Department of Neurology, Danish Multiple Sclerosis Center, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Vermersch, Patrick $u University of Lille, Inserm U1172, Lille Neuroscience & Cognition, Centre Hospitalier Universitaire de Lille, Fédération Hospitalo-Universitaire Precision Medicine in Psychiatry, Lille, France $1 https://orcid.org/0000000309978817 $7 xx0245375
- 700 1_
- $a Leocani, Letizia $u Vita-Salute San Raffaele University, Milan, Italy $u Multiple Sclerosis Center, Casa di Cura Igea, Milan, Italy
- 773 0_
- $w MED00185915 $t Nature reviews. Neurology $x 1759-4766 $g Roč. 20, č. 10 (2024), s. 573-586
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39251843 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105033 $b ABA008
- 999 __
- $a ok $b bmc $g 2263635 $s 1240017
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 20 $c 10 $d 573-586 $e 20240909 $i 1759-4766 $m Nature reviews. Neurology $n Nat Rev Neurol $x MED00185915
- LZP __
- $a Pubmed-20250121
